Biomedical data silos, driven by privacy concerns and proprietary restrictions, impede scientific progress and result in preventable harm. This chapter examines the critical tension between safeguarding patient privacy and enabling open access to biomedical data, with a focus on aging and longevity research. Through case studies—such as fatal medication errors due to opaque electronic health records (EHRs) and delayed diagnoses from non-interoperable systems—we illustrate how restricted data access directly compromises patient safety and stifles innovation. Comparisons to fields like artificial intelligence highlight the transformative potential of open data: initiatives such as ImageNet catalyzed breakthroughs by democratizing access, whereas fragmented EHRs and siloed aging cohorts perpetuate inefficiency, irreproducibility, and duplicated efforts. The analysis extends to post-mortem data, where stringent privacy laws lock away critical longitudinal insights, exacerbating knowledge loss. While ethical frameworks like HIPAA and GDPR prioritize individual rights, we argue that overly cautious policies now hinder collective gains. Technological solutions—including de-identification, federated learning, and data trusts—offer pathways to balance privacy with responsible sharing. The “transhumanist’s dilemma” frames the societal choice: prioritize immediate data security or embrace controlled openness to accelerate longevity breakthroughs. We advocate for policy reforms, incentivized data sharing, and public engagement to transform biomedical data into a common good. By leveraging modern privacy-preserving tools, we propose a recalibrated equilibrium where ethical safeguards coexist with accelerated discovery, unlocking the potential to extend healthy human lifespans while upholding trust in medical systems.